• Bruce N. Cronstein
  • Joseph R. Bertino

Part of the Milestones in Drug Therapy book series (MDT)

Table of contents

  1. Front Matter
    Pages I-IX
  2. Joseph R. Bertino
    Pages 1-7
  3. James O’Leary, Alexander Losev, Franco M. Muggia
    Pages 31-48
  4. Barton A. Kamen, Richard I. Drachtman
    Pages 49-63
  5. Graciela S. Alarcón, Sarah L. Morgan
    Pages 83-108
  6. Ana Monteagudo, Ilan E. Timor-Tritsch
    Pages 125-136
  7. Back Matter
    Pages 137-139

About this book


Although surprising, it seems fitting that a drug developed at the dawn of the era of rational drug design and therapeutics, methotrexate, should remain in common use for the therapy of so many different kinds of illnesses. Moreover, methotrexate has completely revolutionized the way in which medicine is practiced in a number of speciality areas. First developed to treat malignancies, methotrexate is now commonly used to treat gynecological problems, inflammatory arthritis, skin disease and probably other ailments as well. This work is designed to give a broad overview of the history of methotrexate's development, its prior use and its current therapeutic uses. As discussed in Chapter I, aminopterin and methotrexate were designed to inhibit mammalian folate metabolism but the concept of folic acid antag­ onism was soon applied to the development of antibacterial and anti­ parasitic agents. Trimethoprim and sulfa drugs were among the first antibiotics developed and they also remain quite useful today for the treat­ ment of a variety of infections.


cancer diseases medicine pathogenesis psoriasis research rheumatic diseases rheumatism

Editors and affiliations

  • Bruce N. Cronstein
    • 1
  • Joseph R. Bertino
    • 2
  1. 1.Division of RheumatologyNew York University Medical CenterNew YorkUSA
  2. 2.Programm in Molecular and Pharmacologic TherapeuticsMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Bibliographic information